This study investigates advanced metastatic pancreatic cancer. It evaluates the use of an investigational medication in combination with other treatments.
The study focuses on evaluating the safety and effectiveness of the investigational combination treatment for patients with this condition.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic cancer who have not received prior systemic therapy are eligible. Participants must have an ECOG performance status of 0-1 and meet certain health criteria.
- Study details: Participants will receive either the investigational treatment or a standard treatment. The study includes a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.